Paz-Ares L, et al. Overall survival with durvalumab plus etoposide-platinum in first-line extensive-stage SCLC: results from the CASPIAN study. Abstract PL02.11. WCLC 2019, 7-10 september, Barcelona, Spanje.
Auto-immuunziekte geen contra-indicatie voor PD-(L)1-remmer
jul 2022 | Immuuntherapie